| (Values in U.S. Thousands) | Dec, 2025 | Dec, 2024 | Dec, 2023 | Dec, 2022 | Dec, 2021 |
| Sales | 120 | 20 | 120 | 3,520 | 590 |
| Sales Growth | +500.00% | -83.33% | -96.59% | +496.61% | +2,850.00% |
| Net Income | -14,770 | -14,860 | -13,770 | -14,010 | -3,890 |
| Net Income Growth | +0.61% | -7.92% | +1.71% | -260.15% | -168.28% |
Ainos Inc WT (AIMDW)
Ainos Inc WT (AIMDW)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] by (Cboe BZX)
[[ item.lastPrice ]] [[ item.priceChange ]] ([[ item.percentChange ]]) [[ item.tradeTime ]] [NASDAQ]
[[ item.bidPrice ]] x [[ item.bidSize ]] [[ item.askPrice ]] x [[ item.askSize ]]
[[ session ]] [[ item.lastPriceExt ]] [[ item.priceChangeExt ]] ([[ item.percentChangeExt ]]) [[ item.tradeTimeExt ]]
for [[ item.sessionDateDisplayLong ]]
Ainos, Inc. has evolved from a niche biotechnology and medical diagnostics developer into a company pioneering a new category of artificial intelligence known as SmellTech or Smell AI. Centered on its flagship AI Nose platform, Ainos digitizes scent into machine-readable Smell ID data for intelligent sensing applications across robotics, smart manufacturing, semiconductors and healthcare infrastructure, while maintaining selective legacy therapeutic programs. Ainos is incorporated in Texas.
Fiscal Year End Date: 12/31